Pharmacological profile of MEN91507, a new CysLT1 receptor antagonist

European Journal of Pharmacology

Volumn 451, Issue 3, 2002, Pages 317-326

  Cabré, Francesc ^a   Carabaza, Assumpta ^a   García, Ana Maria ^a   Calvo, Lidia ^a   Cucchi, Paola ^b   Palomer, Albert ^a   Pascual, Jaume ^a   García, Maria Lluisa ^a   Manzini, Stefano ^b   Lecci, Alessandro ^b   Crea, Attilio ^b   Maggi, Carlo Alberto ^b  

^a Menarini Research   (Spain)

^b Menarini Ricerche SpA   (Italy)

Author keywords

Airway inflammation; Asthma; Bronchoconstriction; CysLT receptor; Leukotriene D4; Leukotriene receptor antagonist

Indexed keywords

8 [2 [4 [4 (4 FLUOROPHENYL)BUTYLOXY]PHENYL]VINYL] 4 OXO 2 (5 1H TETRAZOLYL) 4H 1 BENZOPYRAN SODIUM; DIMETHYL SULFOXIDE; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MEN 91507; MONTELUKAST; PRANLUKAST; UNCLASSIFIED DRUG; ZAFIRLUKAST;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRONCHOSPASM; CALCIUM CELL LEVEL; CELL DIFFERENTIATION; CELL MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG SELECTIVITY; GUINEA PIG; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

ADMINISTRATION, ORAL; ANIMALS; BENZOPYRANS; BINDING, COMPETITIVE; BRONCHOCONSTRICTION; CELL MEMBRANE; CELLS, CULTURED; DRUG INTERACTIONS; GUINEA PIGS; HUMANS; INJECTIONS, INTRAVENOUS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; LUNG; MALE; MEMBRANE PROTEINS; RECEPTORS, LEUKOTRIENE; TETRAZOLES;

EID: 0037144226     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02232-X     Document Type: Article

References (36)

1. 4 receptors. J. Pharmacol. Exp. Ther. 248:1989;581-588.
2. Arunlakshana A.D., Schild H.O. Some quantitative uses of drug agonists. Br. J. Pharmacol. 108:1959;. (24 pp.).
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal. Biochem. 75:1976;248-254.
4. 4 binding sites in guinea-pig lung. Prostaglandins. 35:1988;503-513.
5. Claesson H.E., Dahlen S.E. Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs. J. Intern. Med. 245:1999;227-295.
6. Dockhorn R.J., Baumgartner R.A., Leff J.A., Noonan M., Vandormael K., Stricker W., Weinland D.E., Reiss T.F. Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients. Thorax. 55:2000;260-265.
7. 4 receptor in human lung and guinea pig lung. Eur. J. Pharmacol. 244:1993;239-250.
8. Gorenne I., Norel X., Brink C. Cysteinyl leukotriene receptors in the human lung: what's new? Trends Pharmacol. Sci. 17:1996;342-345.
9. Grynkiewicz G., Poenie M., Tsien R.Y. A new generation of indicators with greatly improved fluorescence properties. J. Biol. Chem. 260:1985;3440-3450.
10. Hamilton A., Faiferman I., Stober P., Watson R.M., O'Byrne P.M. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J. Allergy Clin. Immunol. 102:1998;177-183.
11. Heise C.E., O'Dowd B.F., Figueroa D.J., Sawyer N., Nguyen T., Im D.S., Stocco R., Bellefeuille J.N., Abramovitz M., Cheng R., Williams D.L.J., Zeng Z., Liu Q., Ma L., Clements M.K., Coulombe N., Liu Y., Austin C.P., George S.R., O'Neill G.P., Metters K.M., Lynch K.R., Evans J.F. Characterization of human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 275:2000;30531-30536.
12. Jenkinson D.H. How we describe competitive antagonists: three questions of usage. Trends Pharmacol. Sci. 12:1991;53-54.
13. 4 receptor antagonist. Can. J. Physiol. Pharmacol. 73:1995;191-201.
14. Kenakin T. Allotopic, noncompetitive and irreversible antagonism. Pharmacological Analysis of Drug-Receptor Interaction. 2nd ed. 1993;323-343 Raven Press, New York.
15. Krell R.D., Aharony D., Buckner C.K., Keith R.A., Kusner E.J., Snyder D.W., Bernstein P.R., Matassa V.G., Yee Y.K., Brown F.J., Hesp B., Giles R.P. The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist. Am. Rev. Respir. Dis. 141:1990;978-987.
16. Lane S.J. Leukotriene antagonism in asthma and rhinitis. Respir. Med. 92:1998;795-809.
17. Leff J.A., Busse W.W., Pearlman D., Bronsky E.A., Kemp J.A., Hendeles L., Dockhorn R., Kundu S., Zhang J., Seidemberg B.C., Reiss T.F. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Engl. J. Med. 339:1998;147-152.
18. Lipworth B.J. Leukotriene-receptor antagonists. Lancet. 353:1999;57-62.
19. Lynch K.R., O'Neill G.P., Liu Q., Im D.S., Sawyer N., Metters K.M., Coulombe N., Abramovitz M., Figueroa D.J., Zeng Z., Connolly B.M., Bai C., Austin C.P., Chateauneuf A., Stocco R., Greig G.M., Kargman S., Hooks S.B., Hosfield E., Williams D.L., Ford-Hutchinson A.W., Caskey C.T., Evans J.F. Characterization of the human cysteinyl leukotriene Cys-leukotriene 1 receptor. Nature. 399:1999;789-793.
20. Markham A., Faulds D. Montelukast. Drugs. 56:1998;251-256.
21. 4 binding site in cellular membranes. J. Biol. Chem. 269:1994;12816-12823.
22. 4 receptor in guinea-pig lung. Eur. J. Pharmacol. 102:1984;1-11.
23. Munson P.J., Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand-binding sytems. Anal. Biochem. 107:1980;220-239.
24. Nakagawa N., Obata T., Kobayashi T., Okada Y., Nambu F., Terawaki T., Aishita H. In vivo pharmacologic profile of ONO-1078: a potent, selective and orally active peptide leukotriene (leukotriene) antagonist. Jpn. J. Pharmacol. 60:1992;217-225.
25. Nathan R.A., Bernstein J.A., Bielory L., Bonuccelli C.M., Calhoun W.J., Galant S.P., Hanby L.A., Kemp J.P., Kylstra J.W., Nayak A.S., O'Connor J.P., Schwartz H.J., Southern D.L., Spector S.L., Williams P.V. The Accolate Trialists Group. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J. Allergy Clin. Immunol. 102:1998;935-942.
26. 4 functional activity with binding affinity. Eur. J. Pharmacol. 143:1987;323-334.
27. Nothacker H.-P., Wang Z., Zhu Y., Reinscheid R., Lin S.H.S., Civelli O. Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol. Pharmacol. 58:2000;1601-1608.
28. Obata T., Okada Y., Motoishi M., Nakagawa N., Terawaki T., Aishita H. In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. Jpn. J. Pharmacol. 60:1992;227-237.
29. Roquet A., Dahlen B., Kumlin M., Ihre E., Anstren G., Binks S., Dahlen S.E. Combined antagonism of leukotriene and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am. J. Respir. Crit. Care Med. 155:1997;1856-1863.
30. Rovati G.E., Capra V., Nicosia S. More on the classification of cysteinyl leukotriene receptors. Trends Pharmacol. Sci. 18:1997;148-149.
31. Sarau H.M., Ames R.S., Chambers J., Ellis C., Elshourbagy N., Foley J.J., Schmidt D.B., Muccitelli R.M., Jenkins O., Murdock P.R., Herrity N.C., Halsey W., Sathe G., Muir A.I., Nuthulaganti P., Dytko G.M., Buckley P.T., Wilson S., Bergsma D.J., Hay D.W. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol. Pharmacol. 56:1999;657-663.
32. Smith L.J. A risk-benefit assessment of antileukotrienes in asthma. Drug Saf. 19:1998;205-218.
33. 2 receptor. Biochem. Biophys. Res. Commun. 274:2000;316-322.
34. Tomari S., Shimoda T., Kawano T., Mitsuta K., Obase Y., Fukushima C., Matsuse H., Kohno S. Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclometasone in patients with moderate or severe asthma. Ann. Allergy Asthma Immunol. 87:2001;156-161.
35. 4. Am. J. Physiol. 261:1991;L164-L171.
36. Wilson A.M., Dempsey O.J., Sims E.J., Lipworth B.J. A comparison of topical budosenide and oral montelukast in seasonal allergic rhinitis and asthma. Clin. Exp. Allergy. 31:2001;616-624.